Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis
June 02, 2015 07:30 ET
|
Melinta Therapeutics
New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more
than 150 other major food companies, retailers, and human and
animal health stakeholders at...
Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI
January 07, 2015 13:40 ET
|
Melinta Therapeutics
New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced positive top-line results from the first of two
Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...
Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy
August 14, 2014 10:38 ET
|
Scienta Communications
NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Christopher Kiritsy to the Company's
Board of Directors. Mr. Kiritsy is currently president,...
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
August 11, 2014 12:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced top-line results of a Phase 1 clinical study that
demonstrated that the administration of single doses of...
Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
July 24, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that the company and investigators will be making eight
presentations at the annual Interscience Conference...
Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference
June 17, 2014 14:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that CEO Mary Szela will be presenting at the annual JMP
Securities Healthcare Conference in New York, NY....
Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections
May 05, 2014 11:27 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that patient enrollment has commenced in a Phase 3 trial
of oral and intravenous (I.V.) delafloxacin, a...
Melinta Therapeutics to Present at Needham & Company's Annual Healthcare Conference
April 03, 2014 14:38 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, April 3, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be presenting a corporate update at Needham...
Melinta Therapeutics Prepares for Late-Stage Product Launches with Appointment of Sue Cammarata, M.D. as Chief Medical Officer
November 19, 2013 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Sue
Cammarata, M.D. as chief medical officer. In this role, Dr.
Cammarata will be...
Melinta Therapeutics Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals
October 07, 2013 09:51 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. & NEW YORK, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., formerly Rib-X Pharmaceuticals,
today announced the launch a new corporate identity, an...